已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort

医学 内科学 肝细胞癌 比例危险模型 倾向得分匹配 回顾性队列研究 危险系数 队列 生存分析 肝移植 多元分析 置信区间 肿瘤科 外科 胃肠病学 移植
作者
Zhihao Li,I. Chen,Leonardo Centonze,Christian Tibor Josef Magyar,Woo Jin Choi,Sachin Shah,Grainne M. O’Kane,Arndt Vogel,Luciano De Carlis,Jan Lerut,Quirino Lai,Neil Mehta,Chao‐Long Chen,Gonzalo Sapisochín
出处
期刊:Liver Transplantation [Lippincott Williams & Wilkins]
卷期号:31 (4): 450-463 被引量:3
标识
DOI:10.1097/lvt.0000000000000501
摘要

Posttransplant HCC recurrence significantly impacts survival, yet its management is challenging due to limited evidence. With recent advancements in HCC treatment, updated data on managing recurrent diseases are needed. In this retrospective study across 6 centers (2000-2022), we employed Cox proportional-hazards regression and log-rank tests to assess survival differences. A prognostic score model was developed to categorize patient survival. The efficacy of tyrosine kinase inhibitors was evaluated through propensity score matching. In our study, 431 of 3349 (14%) patients with HCC who underwent transplantation developed recurrence within a median interval of 18 (IQR: 9-32) months. One hundred forty-seven (34%) underwent curative-intent treatments, 207 (48%) received palliative treatments, and 77 (18%) were given best-supportive care. Patients undergoing curative-intent treatments had better survival from the time of recurrence with a median survival of 45 (95% CI: 36-63) months and 1/3/5-year survival of 90%/56%/43% compared to those receiving noncurative treatments (median: 11 [95% CI: 10-13] mo, 1/3/5-y survival of 46%/10%/7%, log-rank p < 0.001). Patients with recurrence diagnosed in the era 2018-2022 showed improved survival over the previous era (HR 0.64 [95% CI: 0.47-0.86]). Multivariable analysis identified 5 prognostic factors: ineligibility for curative-intent treatment (HR: 3.5 [95% CI: 2.7-4.6]), recurrence within 1 year (HR: 1.7 [95% CI: 1.3-2.1]), poor tumor differentiation (HR: 1.5 [95% CI: 1.1-1.9]), RETREAT score ≥3 (HR: 1.4 [95% CI: 1.1-1.8]), and alpha-fetoprotein at recurrence ≥400 ng/mL (HR: 1.4 [95% CI: 1.1-1.9]). These factors contributed to a prognostic scoring system (0-9) that stratified patients into 3 prognosis groups. Both propensity score-matched analysis and multivariable regression indicated that lenvatinib was not statistically superior to sorafenib in terms of efficacy. Curative-intent treatments should be advocated for patients with posttransplant recurrence whenever possible. Prognostic factors linked to aggressive tumor biology significantly influence survival. Advancements in HCC management have improved survival outcomes over the past 5 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lijinyi发布了新的文献求助10
2秒前
完美世界的应助被wonderfulwisdom采纳,获得10
3秒前
3秒前
3秒前
4秒前
务实元风发布了新的文献求助10
4秒前
5秒前
SS完成签到 ,获得积分10
6秒前
丰富的绮波完成签到 ,获得积分10
6秒前
TS发布了新的文献求助10
7秒前
8秒前
8秒前
9秒前
samifranco发布了新的文献求助10
11秒前
活力广缘发布了新的文献求助10
11秒前
真实的芒果完成签到,获得积分10
12秒前
缺口口发布了新的文献求助10
12秒前
lmd完成签到 ,获得积分10
12秒前
ltttttt发布了新的文献求助10
13秒前
放青松发布了新的文献求助10
13秒前
13秒前
快乐的梦易完成签到,获得积分20
14秒前
14秒前
科研通AI6.4的应助被13508104971采纳,获得10
15秒前
华仔的应助被追寻的夏烟采纳,获得10
15秒前
风笛完成签到 ,获得积分10
16秒前
木子完成签到 ,获得积分10
16秒前
17秒前
Alanza完成签到 ,获得积分10
18秒前
ichenjun发布了新的文献求助10
18秒前
科目三的应助被生动飞凤采纳,获得30
18秒前
molihuakai的应助被老王采纳,获得10
18秒前
19秒前
华仔的应助被科研通管家采纳,获得10
20秒前
Jasper的应助被科研通管家采纳,获得10
20秒前
20秒前
Ava的应助被科研通管家采纳,获得10
20秒前
null的应助被科研通管家采纳,获得10
20秒前
null的应助被科研通管家采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179129
求助须知:如何正确求助?哪些是违规求助? 9569710
关于积分的说明 21806324
捐赠科研通 7774507
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556912
邀请新用户注册赠送积分活动 2478649